Sinovac Biotech, Ltd. (AMEX: SVA) is one of the emerging biotech companies in China. Sinovac (also known in China as Beijing Kexing Bioproducts) specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and “SARS”. While the young company has gained national recognition for its Hepatitis A vaccine, they are the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS. For further information, visit the company website at: www.Sinovac.com.
- 17 years ago
QualityStocks
Sinovac Biotech, Ltd. (AMEX: SVA)
Tags Rodman & Renshaw
Related Post
-
Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Pursues Growth with Santa Fe and Satellites, Offers Upside in Gold Exploration and Development
Lahontan Gold is focused on unlocking value within projects that have historic production, existing infrastructure…
-
Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Builds Domestic Supply Chain Using RapidSX Technology
China’s actions have dramatically escalated since April 2025, when it announced export restrictions. Once raw…
-
Forward Industries Inc. (NASDAQ: FORD) Is ‘One to Watch’
Forward Industries is the largest publicly traded Solana treasury platform with more than 6.8 million…